

# HLM006474

Catalog No: tcsc3180



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

353519-63-8

**Formula:**

$C_{25}H_{25}N_3O_2$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 19.4$  mg/mL (48.56 mM)

**Observed Molecular Weight:**


399.48

## Product Description

HLM006474 is a pan **E2F** inhibitor, which inhibits E2F4 DNA-binding with an **IC<sub>50</sub>** of 29.8  $\mu$ M in A375 cells.

IC50 & Target: IC50: 29.8  $\mu$ M (E2F4 DNA-binding)<sup>[1]</sup>

***In Vitro:*** HLM006474 shows little activities against E2F4 DNA-binding in A375 cells at 10 and 20  $\mu$ M, apparently inhibits E2F4 DNA-binding at 40  $\mu$ M, and increasingly suppresses the effect at 60 and 80  $\mu$ M concentrations. HLM006474 (40  $\mu$ M) inhibits E2F4 activity via suppression of its DNA-binding activity and down regulation of its expression. HLM006474 (40  $\mu$ M) also significantly induces apoptosis in A375 and 231 cell lines for 24 hours. HLM006474 dramatically reduces cyclin D3 protein expression, and is a potent inducer of PARP cleavage<sup>[1]</sup>. HLM006474 reduces the viability of both SCLC and NSCLC lines with IC<sub>50</sub> ranging from 15 to 75  $\mu$ M. HLM006474 (60  $\mu$ M) increases the expression of several known E2F-regulated genes after short treatments in H292 and H1299 cell lines. HLM006474 (20  $\mu$ M) weakly synergizes with paclitaxel, but there is antagonism between HLM006474 and cisplatin and gemcitabine in H1299 cells<sup>[2]</sup>. HLM006474 leads to a decrease in the mRNA levels of MAD2. Furthermore, HLM006474 apparently suppresses the increase of Mad2 protein and pRb-S780 signal but not the level of Skp2 protein in human lung cancer A549 cells<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!